Niki BioSolutions Inc NIKI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
-
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
-
Niki BioSolutions’ Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation’s “Rett Research Tool Belt” Series
-
Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
-
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
-
Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics
-
Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $1.76
- Day Range
- $1.68–1.83
- 52-Week Range
- $0.60–12.24
- Bid/Ask
- $1.61 / $1.70
- Shares Outstanding
- 3.12M
- Market Cap
- $1.38M
- Volume/Avg
- 69,650 / 95,991
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Niki BioSolutions Inc is a clinical-stage life sciences company focused on unmet medical needs and providing genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations. Its activities include the development and application of proprietary technologies to support precision medicine across therapeutic areas including brain health and oncology. The company also collaborates with academic centers, disease foundations, and biopharmaceutical companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.aptorumgroup.com
Valuation
|
Metric
|
NIKI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.06 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NIKI
Financial Strength
|
Metric
|
NIKI
|
|---|---|
Quick Ratio | 0.75 |
Current Ratio | 0.78 |
Interest Coverage | −13.38 |
Quick Ratio
NIKI
Profitability
|
Metric
|
NIKI
|
|---|---|
Return on Assets (Normalized) | −10.85% |
Return on Equity (Normalized) | −8.51% |
Return on Invested Capital (Normalized) | −10.99% |
Return on Assets
NIKI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!&VCKf$ | LOCK|<m>Hp | $139B | |||
| Moderna Inc
MRNA
| LOCK|L?v>Tm | LOCK|!!^ | $103B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|H><@z&F | LOCK|$sFz | $96B | |||
| argenx SE ADR
ARGX
| LOCK|#Gr&b# | LOCK|r$ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?g##lz | LOCK|>f^ | $45B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<<clp#k@ | LOCK|cgYlS | $30B | |||
| Incyte Corp
INCY
| LOCK|d^kHdPJ | LOCK|Ns | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|mnF&n<W | LOCK|$$! | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<^cW?#b | LOCK|?L>#< | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|%BQZ<?s | LOCK|w%z | $15B |
United States